Bone Anabolic Effects of S-40503, a Novel Nonsteroidal Selective Androgen Receptor Modulator (SARM), in Rat Models of Osteoporosis(Pharmacology)
スポンサーリンク
概要
- 論文の詳細を見る
A novel nonsteroidal androgen receptor (AR) binder, S-40503, was successfully generated in order to develop selective androgen receptor modulators (SARMs). We evaluated the binding specificity for nuclear receptors (NRs) and osteoanabolic activities of S-40503 in comparison with a natural nonaromatizable steroid, 5a-di-hydrotestosterone (DHT). The compound preferentially bound to AR with nanomolar affinity among NRs. When S-40503 was administrated into orchiectomized (ORX) rats for 4 weeks, bone mineral density (BMD) of femur and muscle weight of levator ani were increased as markedly as DHT, but prostate weight was not elevated over the normal at any doses tested. In contrast, DHT administration caused about 1.5-fold increase in prostate weight. The reduced virilizing activity was clearly evident from the result that 4-week treatment of normal rats with S-40503 showed no enlargement of prostate. To confirm the bone anabolic effect, S-40503 was given to ovariectomized (OVX) rats for 2 months. The compound significantly increased the BMD and biomechanical strength of femoral cortical bone, whereas estrogen, anti-bone resorptive hormone, did not. The increase in periosteal mineral apposition rate (MAR) of the femur revealed direct bone formation activity of S-40503. It was unlikely that the osteoanabolic effect of the compound was attribute to the enhancement of muscle mass, because immobilized ORX rats treated with S-40503 showed a marked increase in BMD of tibial cortical bone without any actions on the surrounding muscle tissue. Collectively, our novel compound served as a prototype for SARMs, which had unique tissue selectivity with high potency for bone formation and lower impact upon sex accessory tissues.
- 公益社団法人日本薬学会の論文
- 2003-11-01
著者
-
Yamamoto N
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
Nakamura T
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
HANADA Keigo
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
-
FURUYA Kazuyuki
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
-
YAMAMOTO Noriko
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
-
NEJISHIMA Hiroaki
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
-
ICHIKAWA Kiyonoshin
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
-
NAKAMURA Tsutomu
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
-
MIYAKAWA Motonori
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
-
AMANO Seiji
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
-
SUMITA Yuji
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
-
OGURO Nao
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd.
-
Oguro Nao
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
Amano Seiji
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
Sumita Yuji
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
Yamamoto Naofumi
Department Of Neurosurgery Tokyo Medical And Dental University
-
Miyakawa Motonori
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
Nejishima Hiroaki
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
Ichikawa Kiyonoshin
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
Hanada Keigo
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
Nakamura Tsutomu
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
Furuya K
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
-
Yamamoto Noriko
Central Research Laboratories Kaken Pharmaceutical Co. Ltd.
関連論文
- Bone Anabolic Effects of S-40503, a Novel Nonsteroidal Selective Androgen Receptor Modulator (SARM), in Rat Models of Osteoporosis(Pharmacology)
- A Highly Efficient Dye-sensitized Solar Cell Based on a Triarylamine-functionalized Ruthenium Dye
- The Diverse Effects of a Chinese Medicine, Qing Nao Yi Zhi Fang, on the Proliferation of Human Arterial Smooth Muscle Cells and Endothelial Cells(Pharmacology)
- Progressive Development of the Osteoblast Phenotype during Differentiation of Osteoprogenitor Cells Derived from Fetal Rat Calvaria : Model for in Vitro Bone Formation
- Prolapsus Uteri in Pelvic Floor Disorders
- The Novel Non-steroidal Selective Androgen Receptor Modulator S-101479 Has Additive Effects with Bisphosphonate, Selective Estrogen Receptor Modulator, and Parathyroid Hormone on the Bones of Osteoporotic Female Rats
- Mechanism of the Tissue-Specific Action of the Selective Androgen Receptor Modulator S-101479